# CD8+ T-cell clones against cancer-testis antigens in metastatic melanoma (Fred Hutchinson phase 1)

Source: https://onco.cc/trials/nct00045149/  
OnCo record `nct00045149` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A Seattle safety trial of killer T cells grown to recognise cancer-testis proteins, which melanomas can carry but most normal adult tissues do not. It ran from 2002 to 2005.

## Summary

The registry describes a phase I safety study of autologous CD8+ antigen-specific T-cell clones targeting cancer-testis antigens in metastatic melanoma, started in October 2002 and completed in June 2005; no enrolment figure is given (ClinicalTrials.gov NCT00045149). Cassian Yee is listed as study chair, the sponsor is Fred Hutchinson Cancer Center with the National Cancer Institute as collaborator, and the interventions are aldesleukin and therapeutic T cells (ClinicalTrials.gov NCT00045149). No results are posted.

## Fields

- Kind: Trial
- Status: completed
- Last checked: 2026-11-05
- Registry id: NCT00045149
- Phase: 1
- Setting: Metastatic melanoma: autologous CD8+ antigen-specific T-cell clones targeting cancer-testis antigens, with aldesleukin
- Sponsor: Fred Hutchinson Cancer Center, with the National Cancer Institute
- Result: No results posted on ClinicalTrials.gov.

## Sources

- ClinicalTrials.gov NCT00045149: https://clinicaltrials.gov/study/NCT00045149

## Connected records

- cancers: [Melanoma](https://onco.cc/cancers/melanoma/)
- drugs: [Aldesleukin (high-dose IL-2)](https://onco.cc/drugs/aldesleukin/)
- institutions: [Fred Hutchinson Cancer Center](https://onco.cc/institutions/fred-hutch/), [National Cancer Institute (NIH)](https://onco.cc/institutions/nci/)
- terms: [Endogenous T-cell therapy](https://onco.cc/terms/endogenous-t-cell-therapy/)
- people: [Cassian Yee](https://onco.cc/people/cassian-yee/)

---
JSON: https://onco.cc/api/v1/entities/nct00045149.json